Physician profile
Mark K Chang
NPI 1871607507
$141,381.19
in general payments reported to CMS, 2019-2025
15 companies · $16K in 2025
The $16K reported for 2025 was more than what 90% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $12K · 2021: $20K · 2022: $17K · 2023: $32K · 2024: $33K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $80K · Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $80,000.00 |
| Food and Beverage | $1,340.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medyssey USA, INC | $136,800.00 | 2019-2025 | |
| Abbott Laboratories | $1,865.96 | 2019-2025 | Penta, Proclaim |
| Wenzel Spine, INC. | $1,375.27 | 2019-2020 | |
| Arteriocyte Medical Systems, INC. | $532.04 | 2019-2025 | Magellan |
| Alphatec Spine, INC | $182.11 | 2019 | |
| Stryker Corporation | $126.64 | 2021-2025 | Spinejack, Adherus Autospray Dural Sealant, Duramatrix |
| Medtronic, INC. | $102.95 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Carbofix Spine INC | $83.66 | 2022 | |
| Surgalign Spine Technologies, INC. | $83.59 | 2019-2020 | |
| Abbvie INC. | $56.17 | 2024-2025 | |
| Nuvasive, INC. | $51.89 | 2019 | |
| Carlsmed, INC. | $42.73 | 2024 | Aprevo |
| Orthofix Medical, INC. | $31.77 | 2019 | |
| Globus Medical, INC. | $24.94 | 2025 | Senza |
| Nevro Corp. | $21.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.